A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonismwherein X is a nitrogen atom or CH； R1 is -A11-A12； A11 is a single bond or a C1-6 alkylene group； A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.； R2 is -A21-A22； A21 is a single bond or a C1-6 alkylene group； A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.； R3 is a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc； R4 is a hydrogen atom or a C1-6 alkoxy group； R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group； R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.； and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group.
